Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia

Current Medical Research and Opinion

Volumn 25, Issue 11, 2009, Pages 2755-2764

  Ose, Leiv ^a   Budinski, Dragos ^b   Hounslow, Neil ^b   Arneson, Valerie ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Kowa Research Europe Ltd   (United Kingdom)

^c PharmaNet Ltd   (United Kingdom)

Author keywords

Dyslipidaemia; Hypercholesterolaemia; Pitavastatin; Simvastatin; Statins

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MYALGIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT DURATION;

ADULT; AGED; ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; QUINOLINES; SIMVASTATIN; TREATMENT OUTCOME;

EID: 72549107976     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903290886     Document Type: Article

References (45)

1. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996;100:605-610 (Pubitemid 26243669)
2. Sueta CA, Chowdury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999;83:1303-1307 (Pubitemid 29205736)
3. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-467 (Pubitemid 30112269)
4. Foley KA, Simpson RJ, Crouse JR, et al. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003;92:79-81
5. Meyer JW, Schultz JS, O'Donnell JC, et al. Pattern and effectiveness of lipid-lowering therapies in a managed care environment. Value Health 2005;8:601-612
6. McKenney JM. Optimizing LDL-C lowering with statins. Am J Ther 2004;11:54-59
7. Liberopoulos EN, Florentin M, Mikhailidis DP, et al. Compliance with lipidlowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf 2008;7:717-725
8. Ansell BJ. Not getting to goal: the clinical costs of noncompliance. J Manag Care Pharm 2008;14(Suppl S-b):S9-15
9. Bissell P, May CR, Noyce PR. From compliance to concordance: barriers to accomplishing a re-framed model of healthcare interactions. Soc Sci Med 2004;58:851-862 (Pubitemid 37524006)
10. Gotto AM. Treating hypercholesterolemia: looking forward. Clin Cardiol 2003;26:121-128
11. Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multi-center randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS Study). J Am Coll Cardiol 2009;54:293-302
12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22
13. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11:1-160 (Pubitemid 47224473)
14. 4S Study Group. Randomized trial of cholesterol-lowering in 444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389
15. Expert panel on detection evaluation and treatment of high blood cholesterol in adults: executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
16. Grundy SM, Cleeman JI Merz CN, et al American Heart Association: National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials in the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239
17. Wood D, De Backer G, Faergeman O, et al Prevention of heart disease in clinical practice. Recommendations of the second joint Task Force of European and other societies on coronary prevention. Eur Heart J 1998;19:1434-1503
18. Graham I, Atar D, Borch-Johnsen K. et al European guidelines for cardiovascular disease prevention in clinical practice: executive summery. Eur Heart J 2007;28:2375-2414
19. Lee S, Chung N, Kwan J, et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, openlabel, dose-titration study in Korean patients with hypercholesterolemia. Clin Ther 2007;29:2365-2373 (Pubitemid 350298122)
20. Fonesca F, Ruiz A, Cardona-Muñoz E, et al.; DISCOVERY PENTA investigators. The DISCOVERY PENTA study: a direct statin comparison of LDL-C value - an evaluation of rosuvastatin therapy compared with atorvastatin. Curr Med Res Opin 2005;21:1307-1315
21. Strandberg T, Feely J, Sigurdsson E. Twelve week, multicenter, randomized open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high risk adults: a DISCOVERY study. Clin Ther 2004;26:1821-1833 (Pubitemid 40089495)
22. Lins R, Matthys K, Billiouw J, et al. Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study. Clin Nephrol 2004;62:287-294 (Pubitemid 39386805)
23. Yoshitomi Y, Ishii T, Kaneki M, et al. Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: results of a 12-week, open label study. J Atheroscler Thromb 2006;13:108-113
24. European Atherosclerosis Society. The recognition and management of hyperlipidemia in adults: a policy statement of the European Atherosclerosis Society. Eur Heart J 1988;9:571-600 (Pubitemid 18160014)
25. Friedewald W, Levy D, Fredrickson D. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the preparative ultracentrifuge. Clin Chem 1972;18:499-502
26. World Medical Association General Assembly. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Int Bioethique 2004;15:124-129
27. LaRosa J, He J, Vipputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled studies. JAMA 1999;282:2340-2346 (Pubitemid 30013066)
28. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008;337:a2423
29. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004;164:1427-1436 (Pubitemid 38937854)
30. Colleran K, Richards A, Schafer K. Disparities in cardiovascular disease risk and treatment: demographic comparison. J Investig Med 2007;55:415-422 (Pubitemid 351299632)
31. Jacobson T. Overcoming 'ageism' bias in the treatment of hypercholesterolemia review of safety issues with statins in the elderly. Drug Saf 2006;29:421-448
32. Gotto A. Statin therapy and the elderly: SAGE advice? Circulation 2007;115:681-683
33. Bartlett C, Davey P, Dieppe P, et al. Women, older persons, and ethnic minorities: factors associated with their inclusion in randomized trials of 1990 to 2001. Heart 2003;89:327-328
34. Davidson MH, Sun SX, Nag SS, et al. Risk factors for discontinuation of statin medications: evidence from a large national pharmacy claims database. Circulation 2007;116:II-847
35. McGinnis B, Olson KL, Magid D, et al. Factors related to adherence to statin therapy. Ann Pharmacother 2007;41:1805-1811 (Pubitemid 350044342)
36. Kurihara Y, Douzono T, Kawakita K, Nagasaka Y. A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO tablet) - Livalo Effectiveness and Safety (LIVES) Study. Japan Pharmacol Ther 2008;36:709-731
37. Mukhtar R, Reid J, Reckless J-P. Pitavastatin. Int J Clin Pract 2005;59:239-252
38. Pedersen TR, Tobert JA. Simvastatin: a review. Expert Opin Pharmacother 2004;5:2583-2596
39. Kolovou GD, Katerina A, Ioannis V, et al. Simvastatin: two decades in a circle. Cardiovasc Ther 2008;26:166-178
40. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-587 (Pubitemid 28182422)
41. Mölgaard J, Wärjerstam-Elf S, Olsson AG. Efficacy and safety of simvastatin for high risk hypercholesterolemia. Am J Cardiol 1999;83:1043-1048 (Pubitemid 29162788)
42. Brown W. The safety of statins. Curr Opin Lipidol 2008;19:558-562
43. Jones P, Davidson M, Stein E. STELLAR GROUP. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;92:152-160 (Pubitemid 36835963)
44. Fujino H, Yamada I, Shimada S, et al. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase - effect of cMOAT deficiency on hepatobiliary excretion in rats and of mdr1a/b gene disruption on tissue distribution in mice. Drug Metab Pharmacokinet 2002;17:449-456
45. Stein E. Managing dyslipidemia in the high-risk patient. Am J Cardiol 2002;89:50-7C